{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:21:24Z","timestamp":1740162084450,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00549-6","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T11:03:54Z","timestamp":1631790234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-2096","authenticated-orcid":false,"given":"Mario L.","family":"Marques-Piubelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa M.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Malpica","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushanth","family":"Gouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326\u201335.","journal-title":"Blood Adv"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/10428194.2020.1861278","volume":"62","author":"ML Marques-Piubelli","year":"2020","unstructured":"Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, et al. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leukemia Lymphoma. 2020;62:1129\u201335.","journal-title":"Leukemia Lymphoma"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/path.1346","volume":"200","author":"GZ Rassidakis","year":"2003","unstructured":"Rassidakis GZ, Jones D, Lai R, Ramalingam P, Sarris AH, McDonnell TJ, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol. 2003;200:240\u20138.","journal-title":"J Pathol"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.24571","volume":"92","author":"F Zaja","year":"2017","unstructured":"Zaja F, Tabanelli V, Agostinelli C, Calleri A, Chiappella A, Varettoni M, et al. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? Am J Hematol. 2017;92:E1\u2013E2.","journal-title":"Am J Hematol"},{"key":"549_CR7","first-page":"630","volume":"24","author":"HL Li","year":"2011","unstructured":"Li HL, Huang XP, Zhou XH, Ji TH, Wu ZQ, Wang ZQ, et al. Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma. Biomed Environ Sci. 2011;24:630\u201341.","journal-title":"Biomed Environ Sci"},{"key":"549_CR8","first-page":"950","volume":"98","author":"J Julamanee","year":"2015","unstructured":"Julamanee J, Kayasut K, Lekhakula A. The expressions of P53, Bcl-2, and P-glycoprotein and prognostic impact in patients with peripheral T-cell lymphoma (PTCL). J Med Assoc Thai. 2015;98:950\u20136.","journal-title":"J Med Assoc Thai"},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.2019000779","volume":"134","author":"C Amador","year":"2019","unstructured":"Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 2019;134:2159\u201370.","journal-title":"Blood"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403\u201313.","journal-title":"Blood"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bjc.6603951","volume":"97","author":"A Olsson","year":"2007","unstructured":"Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, Tobin G, et al. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Br J cancer. 2007;97:769\u201377.","journal-title":"Br J cancer"},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/108497801750096069","volume":"16","author":"I Contasta","year":"2001","unstructured":"Contasta I, Pellegrini P, Berghella AM, Adorno D. Cell cycle control in cellular homeostasis during the immune response: interactions between TH1, TH2 cytokines, and Bcl2 and p53 molecules. Cancer biotherapy radiopharmaceuticals. 2001;16:63\u201371.","journal-title":"Cancer biotherapy radiopharmaceuticals"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.V128.22.22.22","volume":"128","author":"R Koch","year":"2016","unstructured":"Koch R, Brem E, Clark R, Kupper TS, Letai A, Weinstock DM. A functional characterization of BCL2-family members identifies BH3 mimetics as potential therapeutics in T-cell lymphomas. Blood 2016;128:22\u2013292.","journal-title":"Blood"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Disco. 2021;11:1440\u201353.","journal-title":"Cancer Disco"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00549-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:23:10Z","timestamp":1669918990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00549-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PS is a consultant for Genentech-Roche and has received research support from AstraZeneca. FV received research funding\/support from National Cancer Institute, CRISP Therapeutics, Geron Therapeutics, and honoraria from 13Health, Elsevier, America Registry of Pathology, Congressionally Directed Medical Research Program, and Society of Hematology Oncology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the MD Anderson Cancer Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"153"}}